Literature DB >> 18315585

Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.

P Wahlqvist1, M Karlsson, D Johnson, J Carlsson, S C Bolge, M-A Wallander.   

Abstract

BACKGROUND: Analysis of the burden of gastro-oesophageal reflux disease (GERD) in relation to the severity and frequency of symptoms is essential to identify individuals and groups in whom targeted management is justified. AIM: To describe the relationship between symptoms of GERD and self-reported health-related quality of life (HRQL), work productivity, healthcare utilization and concomitant diseases.
METHODS: US respondents to the Internet-based 2004 National Health and Wellness Survey who had self-reported GERD (n = 10,028, mean age: 52 years, 58% female) were age- and gender-matched to a control group without GERD (n = 10,028). Respondents with GERD were classified according to symptom severity and frequency. HRQL and productivity were assessed using the Short-Form 8 survey (SF-8) and Work Productivity and Activity Impairment questionnaire, respectively.
RESULTS: Symptom frequency increased with increasing symptom severity. Compared with controls, respondents with GERD had more concomitant diseases [mean difference (MD): 1.6], lower SF-8 physical and mental health scores (MD: 4.1 units and 3.1 units, respectively), increased absenteeism (MD: 0.9 h/week), reduced percent productivity at work (MD: 7.5%) and increased healthcare utilization. All tested variables deteriorated with increasing symptom severity and/or frequency.
CONCLUSIONS: Increasing severity and frequency of GERD symptoms is associated with more concomitant diseases, lower HRQL, lower work productivity and increased healthcare utilization, suggesting that patients with moderate or severe GERD should receive targeted management with the most effective treatment strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18315585     DOI: 10.1111/j.1365-2036.2008.03671.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  36 in total

1.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

2.  Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation.

Authors:  Kerstin Röhss; Clive Wilder-Smith; Sara Bokelund-Singh; Mohamed Sagar; Péter Nagy
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

Review 3.  Enhanced endoscopic imaging and gastroesophageal reflux disease.

Authors:  Rupa Banerjee; D Nageshwar Reddy
Journal:  Indian J Gastroenterol       Date:  2011-10-19

4.  The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Authors:  Samira Toghanian; Peter Wahlqvist; David A Johnson; Susan C Bolge; Bengt Liljas
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.

Authors:  Samira Toghanian; David A Johnson; Nils-Olov Stålhammar; Frank Zerbib
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

6.  Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease.

Authors:  T H Taft; J R Triggs; D A Carlson; L Guadagnoli; K N Tomasino; L Keefer; J E Pandolfino
Journal:  Aliment Pharmacol Ther       Date:  2018-03-12       Impact factor: 8.171

7.  The epidemiology of gastroesophageal reflux disease: a survey on the prevalence and the associated factors in a random sample of the general population in the Northern part of Iran.

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Seyed Mehrbod Atshani; Sepideh Chagharvand; Fatemeh Souti
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

Review 8.  Gastroesophageal reflux and rhinosinusitis.

Authors:  Elin-Johanne Katle; Jan G Hatlebakk; Sverre Steinsvåg
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

Review 9.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study.

Authors:  Javier P Gisbert; Alun Cooper; Dimitrios Karagiannis; Jan Hatlebakk; Lars Agréus; Helmut Jablonowski; Javier Nuevo
Journal:  Health Qual Life Outcomes       Date:  2009-10-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.